Chen, Xuejun <br/><br/>
Population pharmacokinetic analysis of orally-administered ruxolitinib (INCB018424 Phosphate) in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET MF).  [electronic resource] 

 -  Journal of clinical pharmacology  Jul 2013 
 - 721-30 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1552-4604 
<br/><br/><label>Standard No.: </label>10.1002/jcph.102  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Clinical Trials, Phase III as Topic<br/>Double-Blind Method<br/>Female<br/>Humans<br/>Janus Kinases--antagonists & inhibitors<br/>Male<br/>Models, Biological<br/>Nitriles<br/>Polycythemia Vera--drug therapy<br/>Primary Myelofibrosis--drug therapy<br/>Protein Kinase Inhibitors--pharmacokinetics<br/>Pyrazoles--administration & dosage<br/>Pyrimidines<br/>Randomized Controlled Trials as Topic<br/>Thrombocythemia, Essential--drug therapy